4th Quarter - Termination

THE MCMANUS GROUP for NOVARTIS

Firm
Client
Income
$40,000
Expenses
—
Terminated
Dec 31, 2019

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Advocacy regarding access to 340B reimbursement.

Foreign entity interest: Novartis AG, Fabrikstrasse 2, 4056 Basel, Switzerland

LobbyistCovered position, as disclosed
JOHN MCMANUS —
BARRETT THORNHILL —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

Legislation amending the Patent Act, including reforms to patent eligible subject matter. S. 1416, the Affordable Prescriptions for Patients Act of 2019.

Foreign entity interest: Novartis AG, Fabrikstrasse 2, 4056 Basel, Switzerland

LobbyistCovered position, as disclosed
JOHN MCMANUS —
BARRETT THORNHILL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1416 (116th)

Medicare/Medicaid MMM

Pharmaceutical coverage and access in Parts A, B, C, and D. S. 2543, the Prescription Drug Pricing Reduction Act, H.R. 19, the Lower Costs, More Cures Act of 2019, and H.R. 3, the Lower Drug Costs Now Act.

Foreign entity interest: Novartis AG, Fabrikstrasse 2, 4056 Basel, Switzerland

LobbyistCovered position, as disclosed
JOHN MCMANUS —
BARRETT THORNHILL —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 19 (116th), S. 2543 (116th), H.R. 3 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.